KYMERA THERAPEUTICS INC (KYMR)
Health Care · Targeted protein degradation / molecular glue therapeutics · NASDAQ
Clinical-stage biotech leveraging targeted protein degradation to create oral small-molecule medicines with biologics-like activity for immunology and other serious diseases.
What KYMERA THERAPEUTICS INC does
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule medicines using targeted protein degradation (TPD), a modality that leverages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The company is primarily targeting immunology programs, including STAT6, IRF5, and IRAK4 pathways, with lead programs KT-621 (in Phase 2b trials for atopic dermatitis and asthma), KT-579 (oral IRF5 degrader in Phase 1), and KT-485/SAR447971 (IRAK4 degrader in collaboration with Sanofi), as well as a CDK2 molecular glue degrader program licensed to Gilead.
Themes: ["targeted protein degradation","immunology / immune-inflammatory diseases","atopic dermatitis","asthma","cell cycle regulation (CDK2)","oral biologics-like medicines"]
Fundamentals
- Price$119.00 as of 2026-07-09 close
- Market cap$9.7B as of 2026-07-10
- 1-year return+162.9% as of 2026-07-09 close
- Net margin-612.0% as of 2026-07-10
- ROE-25.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-12.6% as of 2026-07-10
- Revenue CAGR (3y)-5.7% SEC XBRL
- Beta1.94 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: multiple programs still in Phase 1-2b stages with no approved products, requiring successful completion of trials and regulatory approval to generate revenue","Unprofitability and capital requirements: company is unprofitable with negative net margin of -611.96% and relies on funding to advance pipeline; continued losses and need for capital raises pose financial sustainability risk","Competition from established biologics and alternative modalities: TPD is competing against established injectable biologics for immunology indications, and success depends on demonstrating superior oral convenience and clinical efficacy"]
Competitors & peers
- Gilead Sciences (GILD)
- Sanofi (SNY)
- Incyte Corporation (INCY)
- Principia Biopharma (acquired by Sesen Bio)
- C4 Therapeutics
- Ayala Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.